Episodes of hypercalcaemia and hypercalciuria may be associated with malignant tumours of widely differing types and sites of origin. These disturbances of calcium metabolism are common in patients with carcinoma of the breast, particularly in those with bone metastases. Similar disturbances associated with bone destruction are observed in many patients with multiple myelomatosis (Gutman, Tyson, and Gutman, 1936; Woodard, 1953) .
It has been shown that during these episodes patients are in negative calcium balance and that the hypercalcaemia is not due to excessive absorption of calcium from the gut (Laszlo, Schulman, Bellin, Gottesman, and Schilling, 1952) . Studies of the osteoblastic response to the destruction of bone in these patients have depended on the indirect evidence of the levels of alkaline phosphatase in the plasma, and it has been assumed that the increased levels of this enzyme observed in patients with metastatic tumours of bone have reflected, in the absence of obvious liver damage or metastases, increased new bone formation. Conversely, the normal or low levels of plasma alkaline phosphatase observed in patients with multiple myelomatosis have been interpreted as evidence of a failure of compensatory growth of new bone in the face of destruction by myeloma tissue (Woodard, 1953; Gutman et al., 1936 The availability in recent years of the isotopes 45Ca, 47Ca, and 85Ca has enabled a more detailed study to be made of the turnover of calcium in the body. Short-term studies of the retention of calcium in the body are of some clinical value but they do not give information concerning the way in which the body utilizes the retained calcium (Spencer, Laszlo, and Brothers, 1957) . Methods based on the measurement of isotope clearance rates have indicated that a proportion of the calcium that leaves the extracellular fluid compartment does so by routes other than those of excretion. The rate of loss of this fraction of the extracellular fluid calcium has been assumed to be a measure of the rate of calcification of newly formed bone and has been termed the 'bone accretion rate' (Bauer, Carlsson, and Lindquist, 1955, 1957; Heaney and Whedon, 1958; Fraser, Harrison, and Ibbertson, 1960;  Glass and Nordin, 1963) . Despite the limitation of such an assumption (Heaney and Whedon, 1958) these methods provide useful tools for the assessment of bone activity in a variety of clinical conditions (Bauer et al., 1957; Fraser et al., 1960) .
In the investigation presented here, the accretion rate was determined as a measure of new bone formation, and the rate of urinary calcium excretion was used to assess the degree of bone destruction in patients with carcinoma of the breast, multiple myelomatosis, and Paget's disease of bone. The patients were maintained on a normal hospital diet. 69 METHODS SELECTION OF PATIENTS Six patients with primary malignant tumours who were otherwise in good health and without evidence of bone disease were selected for the control group. Twenty patients with carcinoma of the breast were investigated of whom 14 had radiographic evidence of bone metastases. The latter patients had previously received a variety of treatments including steroids, radiotherapy or adrenalectomy, but at the time of investigation were in relapse. Five patients with Paget's disease of bone and 14 patients with multiple myelomatosis who had skeletal deposits as well as characteristic bone-marrow and plasma protein changes were also investigated.
TECHNIQUE USING 45CALCIUM 45Ca as CaCl2, 25 to 50 /c., was diluted with 10 ml. of 09% saline, sterilized, and injected intravenously. The volume of the injected dose was determined by weighing the container before and after charging the syringe, and by radioassay of syringe residues.
Excreta were collected for 10 to 14 days after the administration of the dose. Urine was passed into 2-5 litre Winchester bottles containing 10 ml. concentrated HCl; faeces were wrapped in polythene sheeting and placed in waxed containers. The volume of each 24-hr. urine sample was measured and an aliquot (usually 50 ml.) was concentrated by wet-ashing with 10 ml. fuming nitric acid. A few drops of hydrogen peroxide were added when the ashing was almost complete to prevent charring of the sample. The white precipitate was dissolved in 2 ml. of 2N HCl and made up to 10 ml. with distilled water. Faecal samples were ashed for 12 hours in a muffle furnace at 600°C. The ash was weighed and a known aliquot (about 01 g.) dissolved in 2N HCI and made up to 100 ml. Of these solutions, 1 ml. aliquots were adjusted to pH 5 with 25% ammonia, the calcium precipitated with saturated ammonium oxalate and estimated by titrating with potassium permanganate (Clark and Collip, 1925) . Further aliquots of the solutions containing 3 to 4 mg. calcium were then pipetted on to 1 cm.2 plastic planchettes fitted into specially constructed perspex centrifuge tubes. Four ml. of a solution containing 1 mg. of Ca/ml. was added to a suitable aliquot of syringe washings and to standard solutions of 45Ca.
These were treated in the same way as the test samples.
After standing overnight the tubes were centrifuged at 2,000 r.p.m. for 20 minutes. The supernatant fluid was decanted and the plastic planchettes were removed and dried at room temperature.
All samples were assayed for radioactivity with a thin end-window GM tube and conventional scaler.
TECHNIQUE USING 35 TO 40 pC. 47CALCIUM The dose was prepared and administered, and the excreta collected as for 4'Ca. In some cases 20 ml. samples of blood were collected at intervals during the first 24 hours.
The excreta were counted directly after dilution to constant volume by placing the Winchester bottle within a ring of 16 GM tubes. Two standard solutions were prepared each containing 5% of the dose, one in [2] [3] [4] [5] litres of water in a Winchester bottle and the second in a wax carton containing cotton wool. A lead filter 2 mm. thick was placed between the specimen and the GM tubes to avoid recording the radiations from 47Scandium which is a daughter isotope of 47Ca and a weak emitter. Fifty ml. aliquots of urine were wet-ashed and the calcium estimated as above. Blood samples were centrifuged and the calcium was precipitated from 10 ml. of plasma with an equal volume of saturated ammonium oxalate. After washing with 2 % ammonia the precipitate was dissolved in 2N HCl for radioassay in a well-type scintillation counter. A standard sample was prepared from a suitable aliquot of the injected solution. The 47Ca was assayed at an E.H.T. voltage and discriminator bias such as to avoid recording activity from 47Scandium. The calcium content of each plasma sample was determined by permanganate titration after the radioassay.
TECHNIQUE USING 1 to 5 ftC. 47CALCIUM Excreta were collected as above. The volume of each urine specimen was measured and 20 ml. wet-ashed and made up to 10 ml. for calcium estimation as described for 45Ca. The remainder of the specimen was evaporated to a small volume and made up to 300 ml. Faecal samples were ashed in a muffle furnace, dissolved in hot dilute HCI, and made up to 300 ml. A standard solution of 47Ca containing a known fraction of the dose was prepared in a similar volume. Samples were assayed by placing each bottle between two scintillation probes constructed with 7 x 5 cm. Nal (TI) crystals mounted in a low background room (Trott, Parnell, Hodt, and Entwistle, 1963) and the activity of energy above 300 Kev. recorded.
CALCULATION OF THE RATE OF CALCIUM ACCRETION IN BONE
Specific activities of urine were expressed as percentage per milligram dose of calcium. Preliminary studies of both blood and urine specimens showed that the mean specific activity of a sample of urine was similar to that of a sample of plasma obtained after an interval of time equal to one third of the period in which the urine was collected. Thus the mean specific activity of a 24-hour urine approximated that of a sample of plasma obtained eight hours after the start of the urine collection. Owing to the small doses of 47Ca used and its short half-life (4 7 days) low activities were present in the plasma; thus the measurement of the mean urinary specific activity obviated the use of large volumes of plasma. The specific activity of plasma calcium, whether measured directly or deduced from the urine data, was adjusted for losses in the excreta by dividing the observed specific activity by the fraction of the dose retained in the body at that time (Fig. 1) . The adjusted specific activity values were plotted on semi-logarithmic paper. A curve was obtained for each investigation which could be analysed into a number of exponential functions. The early mixing components were ignored for these purposes and the last linear part of the curve was assumed to represent the rate at which calcium was lost from the extracellular fluid into semipermanent or permanent bone. 
RESULTS
The values for the exchangeable calcium pool, the calcium accretion rate, and the mean 24-hourly urinary calcium excretion are given in Table I . The six control patients had a mean accretion rate of 24-8 ± 7-7 (S.D.) mg./hr. Although the mean value of 16-7 ± 10-2 mg./hr. for patients with carcinoma of the breast without metastases was lower, this difference was not statistically significant (0-1 < p < 0-2). Patients with bone metastases showed an increase in the accretion rate with a mean value of 45-2 ± 27-9 mg./hr. but only the group of patients who excreted more than 300 mg. of calcium in 24 hours showed an increase in accretion rate, i.e., 50-3 ± 24-6 mg./hr. which was significantly higher than the control value (0-02 < p < 0-05). The mean accretion rate for the patients with The high values of accretion rate observed in the patients with Paget's disease of bone are associated with relatively low excretion of calcium in the urine (Table II) . Previous observations of accretion rate in patients with Paget's disease have shown similar bigh values and they probably reflect the great activity in calcium turnover in the affected bone (Heaney and Whedon, 1958; Bauer et al., 1961) .
Our findings provide some confirmation for the conclusions derived from the earlier observations of the changes in the levels of serum alkaline phosphatase. Woodard (1953) observed raised levels of alkaline phosphatase in about half of her cases of carcinoma of the breast with metastatic bone disease. She also observed that a rise in serum alkaline phosphatase was less common in multiple myelomatosis, and indeed the level of this enzyme was often reduced. Thus by measuring the urinary calcium excretion and the bone accretion rate of calcium by isotope techniques a useful assessment can be made of the rate of calcification of newly formed bone relative to the degree of bone destruction.
